TheraVet S.A. (ALVET.PA)
TheraVet S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Charleroi, BE. The stock last traded at $0.08, up 0.00% on the session, giving a market capitalisation of $10.0M. Its beta of -0.50 implies it has historically moved less than the broad market.
TheraVet S.A. operates as a veterinary biotechnology firm, delivering specialized osteoarticular therapies for animals across Belgium, France, Switzerland, the United Kingdom, and the United States. The company's primary focus is on providing solutions for osteoarthritis, ligament and tendon damage, and bone surgery requirements in felines, canines, and equines. Its product lineup includes BIOCERA-VET, formulated to enhance bone integration and remodeling, and VISCO-VET. The latter is an injectable, hyaluronic acid-based gel that facilitates regeneration, exhibits anti-inflammatory characteristics, boosts the effectiveness of active compounds, and promotes cellular colonization essential for tissue repair. Founded in 2017, TheraVet S.A. has its corporate base situated in Jumet, Belgium.
TheraVet S.A. is most often compared with the following Healthcare names: